Peer-reviewed veterinary case report
Oclacitinib treatment for reactive histiocytosis in 10 dogs
By Cain, Christine L et al.·Published in Veterinary dermatology·2026·Department of Clinical Sciences and Advanced Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of Reactive Histiocytosis With Oclacitinib: A Retrospective Case Series of 10 Dogs.
- Species:
- dog
Plain-English summary
Ten dogs with reactive histiocytosis, a condition causing skin nodules and plaques, were treated with oclacitinib, a medication that helps regulate the immune system. These dogs had previously tried other treatments without success, but all responded well to oclacitinib, with their skin and mouth lesions clearing up within 2 to 12 weeks. The treatment was effective enough that most dogs maintained remission, although a few had minor recurrences that were managed by adjusting the medication dose. Overall, oclacitinib proved to be a promising option for dogs suffering from this challenging condition.
People also search for: dog skin nodules treatment · oclacitinib for dogs · reactive histiocytosis in dogs · dog skin lesions remedies
Abstract
BACKGROUND: Canine reactive histiocytosis is a proliferative disorder of activated interstitial dendritic cells with cutaneous and systemic forms. An immune-mediated aetiology is likely, and systemic immunomodulatory agents such as corticosteroids, tetracycline/niacinamide, ciclosporin, azathioprine and leflunomide have been employed for its management. HYPOTHESIS/OBJECTIVES: The aim of this retrospective case series is to report the clinical features and therapeutic response to oclacitinib in dogs with reactive histiocytosis. ANIMALS: Ten privately owned dogs. MATERIALS AND METHODS: All dogs were diagnosed with reactive histiocytosis based on compatible clinical history, skin lesions and histopathological features, and were treated with oclacitinib as a sole therapy. Immunohistochemical investigation was used to characterise dermal cellular infiltrates for eight of 10 dogs. Clinical features and case outcomes are summarised. RESULTS: All 10 dogs presented with dermal nodules and/or erythematous plaques affecting the head, trunk or limbs; four dogs also had documented or suspected involvement of the nasal or oral cavities. Seven dogs had been treated previously with one or more immunomodulatory agents without durable disease control. All dogs were completely responsive to treatment with oclacitinib, at or slightly above the standard antipruritic dosage. Skin and mucosal lesions resolved within 2-12 weeks. Lesion remission was maintained with oclacitinib monotherapy for varying follow-up times, although four dogs had brief recurrences addressed with adjustments in oclacitinib dosing. CONCLUSIONS AND CLINICAL RELEVANCE: Although reactive histiocytosis can have a naturally waxing and waning course, oclacitinib appears to be rapidly effective for management, even in cases refractory to other immunomodulatory agents or with involvement of the oral or nasal cavities. ANIMAL USE STATEMENT: Animal use was conducted in accordance with the international, national and institutional guidelines for the humane treatment of animals, and with relevant legislation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41603087/